Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Who should not get IV vitamin therapy
Mendelsohn lays out why Vivani shifted from a broad platform story to focusing 90% of the company on a GLP-1 drugdevice product, how theyre using the 505(b)(2) pathway to shorten development by leveraging existing semaglutide data, and why the ability to stop treatment by removing the implant addresses a limitation of long-acting injectables
Activation of GLP-1R in these cells can be monitored by measuring luciferase activity
After 2 h-pretreatment with metformin at 0, 10, 100, or 1000 M, culture medium was changed to HBSS containing 8 mM glucose, and MIN6 cells were incubated for a further 40 min
US$ 20.63
US$ 22.28
US$ 23.47
US$ 25.69
US$ 25.79
